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Abstract
Background: To assess the effect of policies supporting local medicine production to improve access to medicines.
Methods: We adapted the WHO/HAI instruments measuring medicines availability and prices to differentiate local
from imported products, then pilot tested in Ethiopia and Tanzania. In each outlet, prices were recorded for all
products in stock for medicines on a country-specific list. Government procurement prices were also collected.
Prices were compared to an international reference and expressed as median price ratios (MPR).
Results: The Ethiopian government paid more for local products (median MPR = 1.20) than for imports (median
MPR = 0.84). Eight of nine medicines procured as both local and imported products were cheaper when imported.
Availability was better for local products compared to imports, in the public (48% vs. 19%, respectively) and
private (54% vs. 35%, respectively) sectors. Patient prices were lower for imports in the public sector (median
MPR = 1.18[imported] vs. 1.44[local]) and higher in the private sector (median MPR = 5.42[imported] vs. 1.85[local]). In
the public sector, patients paid 17% and 53% more than the government procurement price for local and imported
products, respectively.
The Tanzanian government paid less for local products (median MPR = 0.69) than imports (median MPR = 1.34). In the
public sector, availability of local and imported products was 21% and 32% respectively, with patients paying slightly
more for local products (median MPR = 1.35[imported] vs. 1.44[local]). In the private sector, local products were less
available (21%) than imports (70%) but prices were similar (median MPR = 2.29[imported] vs. 2.27[local]). In the public
sector, patients paid 135% and 65% more than the government procurement price for local and imported products,
respectively.
Conclusions: Our results show how local production can affect availability and prices, and how it can be influenced by
preferential purchasing and mark-ups in the public sector. Governments need to evaluate the impact of local
production policies, and adjust policies to protect patients from paying more for local products.
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Background
Ensuring access to medicines requires policies to im-
prove the availability and affordability of quality-assured
medicines that meet local health needs [1]. Surveys using
the World Health Organization (WHO)/Health Action
International (HAI) tool measuring medicine prices,
availability and affordability [2] have shown poor medi-
cine availability (particularly in the public sector), high
prices in both the public and private sectors, and un-
affordable treatments for those on low wages [3–7]. Use
of the WHO/HAI survey tool has greatly increased
knowledge on medicine prices and availability in low- and
middle-income countries (LMICs), but the analysis does
not differentiate between local and imported products.
Increasingly, governments in LMICs are supporting
local medicine production, expecting that it will result in
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increased availability and lower prices, as well as in-
dustrial and economic benefits [8]. To assist countries
the WHO, in partnership with the United Nations
Conference on Trade and Development (UNCTAD)
and the International Centre for Trade and Sustainable
Development (ICTSD), commenced a project in 2012 on
local production of medical products for improved access
in LMICs. A literature review in Part 1 of the project
found inconclusive evidence as to whether local produc-
tion improved access to medicines [9]. The authors pro-
posed that to shed light on this issue, surveys using the
WHO/HAI survey tool should differentiate between local
and imported medicines [10]. Therefore, in Part 2 of the
project, such a tool was developed and pilot tested.
Objective
The objective of this study was to compare the price
and availability of locally produced and imported
medicines and, in particular, to answer the following
key questions:
 What prices does the government pay, and quantities
procured, for selected medicines that are locally
produced and imported, and how do these prices
compared with public sector patient prices?
 What is the availability and patient price for locally
produced and imported medicines in different
sectors and regions of the country?
 Do prices and availability vary by product type
(originator brands, branded generics and International
Non-proprietary Name (INN) generics)?
 Do prices vary by country of manufacture?
 How do prices compare with international reference
prices?
The WHO/HAI survey tool was adapted to measure
the price and availability of locally produced and
imported medicines, and answer the study questions. In
August 2013 the new tool was pilot tested Tanzania and
Ethiopia, two of the East African countries in the WHO
local production project, with the support of the govern-
ments in both countries.
Pharmaceutical sectors
In Ethiopia there were nine local pharmaceutical manufac-
turers, while in Tanzania there were seven. All made fin-
ished dosage forms, but not active pharmaceutical
ingredients. Prices were not regulated in either country,
nor were mark-ups regulated in the pharmaceutical supply
chain. In Ethiopia, the annual pharmaceutical, supplies and
medical equipment budget was 8.26 billion Birr (approxi-
mately USD$441 million) in 2013/14. The Pharmaceutical
Fund and Supply Agency procures medicines on behalf of
the Ethiopian Government via centralised international
tenders. In Tanzania, the budget for medicines, medical
equipment and building capacity in the health sector was
TShs. 92.05 billion (approximately USD$58 million) in
2013/14. The Medical Stores Department procures medi-
cines on behalf of the Tanzanian Government, also via cen-
tralised international tenders. Both countries award
tenders to the lowest-priced bid submitted by prequalified
suppliers, except local manufacturers are permitted a pref-
erence of up to 25% in Ethiopia and 15% in Tanzania. In
both countries, patients pay for most medicines out-of-
pocket in the public sector (some medicines in the Tanza-
nian public and mission sectors are provided as part of the
consultation fee). Neither country taxes medicines, but
Ethiopia applies a 5% import tariff on finished products.
Method
Study design
Sampling
In each country, patient price and availability data were
collected in the capital and five other regions, as per the
WHO/HAI methodology. In Ethiopia, the survey areas
were Addis Ababa, Oromia, Amhara, Southern Nations,
Nationalities, and Peoples’ Region (SNNPR), Harari and
Afar. In Tanzania, data were collected in Dar es Salaam,
Manyara, Mbeya, Mtwara, Shinyanga and Tabora.
This article reports on the findings from the public
and private sectors. In Ethiopia, 34 public sector outlets
were sampled (hospital pharmacies and health facilities)
and 30 private retail pharmacies. In Tanzania, data were
collected from 33 public sector outlets (hospital phar-
macies and health facilities) and 30 private sector out-
lets (private retail pharmacies, and Accredited Drug
Dispensing Outlets which are privately-owned outlets
licensed to sell certain essential medicines). Data were
also collected from a third sector (mission facilities in
Tanzania, and NGO and municipal pharmacies in
Ethiopia) but are not included here. The data for these
sectors can be accessed in the two country reports on
HAI’s website (http://haiweb.org/what-we-do/price-avail-
ability-affordability/measuring-the-availability-and-prices-
of-locally-produced-and-imported-medicines/).
Current government procurement prices and quan-
tities were also collected. In Ethiopia, these were 2013
tender prices collected from the Pharmaceutical Fund
and Supply Agency. In Tanzania, 2012 tender prices
were collected from the Medical Stores Department.
Medicines
Data were collected and analysed for 25 medicines in
Ethiopia, and 24 in Tanzania (Table 1). The medicines
were selected nationally, were strength- and dosage
form-specific, and were made by at least one local
manufacturer. In each outlet, for each medicine data
were collected on all products in stock with the same
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active ingredient(s), strength and dosage form. The
country of manufacture was identified from product
labels.
Data quality assurance
National investigators were trained in a two-day
workshop which included piloting data collection.
They then trained their survey personnel. Prices were
identified from packs or pharmacy computers. Data
were checked at the end of each day for completeness
and possible errors. Re-surveying three outlets per
country did not reveal any inconsistencies in the data
collected. Data were double-entered into the auto-
mated Excel Workbook. The country of manufacture
and marketing authorization was validated with the
Tanzanian Food and Drug Administration (TFDA),
and checked on the website of the Ethiopian Food,
Medicine and Health Care Administration and Control
Authority (FMHACA).
Data analysis
In this study, local production was defined as products
that were manufactured and packaged/labelled in the
study country.
Availability was based on whether the medicine was in
stock on the day of data collection at the surveyed facility.
All medicines were included in the availability analysis.
International Commercial (INCO) terms were identi-
fied for each product procured by the government. To
be more comparable with prices of locally produced
products, adjustments were made to prices of imports
which did not cover all costs to the national government
store.
For each medicine, where more than one locally pro-
duced or imported product was found in an outlet, the
median unit price was used in the analysis.
Prices were expressed as median price ratios (MPR).
An MPR is the ratio of the price in local currency
(Tanzanian Shilling/Ethiopian Birr) divided by an inter-
national reference price (IRP) converted to local cur-
rency using the exchange rate on the first day of data
collection. The MPR is thus an expression of how much
greater or less the price in the country is than the IRP
e.g. an MPR of 1 means the country price was equivalent
to the IRP, whereas an MPR of 2 means the country
price was twice that of the IRP. In these surveys, use of
IRPs serve as a benchmark for price comparisons be-
tween locally produced and imported medicines. The
IRPs were taken from the 2012 Management Sciences
for Health International Drug Price Indicator Guide
(current at the time of the surveys) for international pro-
curements. They reflect prices that governments in
LMICs could be expected to pay for medicines. Accord-
ing to WHO and HAI, governments in LMICs should be
able to achieve an MPR of 1 when buying medicines,
and WHO considers patient prices are high when MPRs
exceed 4 [11].
For patient prices, an MPR was only calculated for a
medicine when at least four price points were recorded
per sector. For public procurement prices, an MPR was
calculated when one or more prices were recorded. Most
analyses in this article are paired i.e. the analysis includes
only medicines (same strength and dosage forms) where
MPRs were calculated for both local and imported
products.
Prices and availability of all products were also ana-
lysed by product type i.e. originator brands, branded ge-
nerics and International Non-proprietary Name (INN)
generics. An originator brand is the product that was
first authorized world-wide for marketing (usually as a
patented product) and always has a brand name. A
branded generic is a generic equivalent product mar-
keted under a brand name. An INN generic is a generic
equivalent product marketed under its INN name.
Table 1 Survey medicines
Ethiopia Tanzania
Acetyl salicyclic acid 300 mg tab/cap Acetyl salicyclic acid 300 mg tab/cap
Albendazole 100 mg/5 ml suspension Albendazole 100 mg/5 ml suspension
Amoxicillin 250 mg tab/cap Amoxicillin 250 mg tab/cap
Amoxicillin 500 mg tab/cap Amoxicillin 500 mg tab/cap
Chloramphenicol 250 mg tab/cap Chloramphenicol 250 mg tab/cap
Ciprofloxacin 500 mg tab/cap Ciprofloxacin 500 mg tab/cap
Diclofenac 50 mg tab/cap Diclofenac 50 mg tab/cap
Doxycyline 100 mg tab/cap Doxycyline 100 mg tab/cap
Erythromycin 250 mg tab/cap Erythromycin 250 mg tab/cap
Paracetamol 120 mg/5 ml suspension Paracetamol 120 mg/5 ml suspension
Paracetamol 500 mg tab/cap Paracetamol 500 mg tab/cap
Sulfamethoxazole + Trimethoprim
400 mg + 80 mg tab/cap
Sulfamethoxazole + Trimethoprim
400 mg + 80 mg tab/cap
Tetracycline 250 mg tab/cap Tetracycline 250 mg tab/cap
Amitriptyline 25 mg tab/cap Artemeter + Lumefantrine 20 mg +
120 mg tab/cap
Benzathine penicillin 2.4MIU injection Azithromycin 250 mg tab/cap
Chloroquine 50 mg/5 ml syrup Cloxacillin 250 mg tab/cap
Enalapril 10 mg tab/cap Erythromycin 125 mg/5 ml suspension
Fluoxetine 20 mg tab/cap Fluconazole 150 mg tab/cap
Furosemide 40 mg tab/cap Ibuprofen 200 mg tab/cap
Glibenclamide 5 mg tab/cap Quinine sulphate 300 mg tab/cap
Ibuprofen 400 mg tab/cap Salbutamol 4 mg tab/cap
Metoclopramide 5 mg/5 ml syrup Sulfadoxine + Pyrimethamine
500 mg + 25 mg tab/cap
Metronidazole 250 mg tab/cap Sulfamethoxazole + Trimethoprim
200 + 40 mg/5 ml suspension
Phenobarbitone 100 mg tab/cap Zinc sulphate 20 mg dispersible tab
Sodium Chloride 0.9% 1 L IV solution
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Results
Ethiopia
Government procurement prices and quantities
Of the 25 survey medicines, the government procured
21 locally produced medicines (48 products) and 12
imported medicines (13 products). Based on the INCO
terms, 22% was added to the procurement price of nine
products found to be Free Carrier or Free on Board
(15% freight, 0.5% insurance, 1.5% bank charges, 5% im-
port duty) and 7% was added to four products found to
be Cost and Freight (0.5% insurance, 1.5% bank charges,
5% import duty).
Overall, government procurement prices for locally
produced and imported medicines were 1.20 and 0.84
times international reference prices (IRP), respectively
(Table 2). For local products, half ranged from 0.99-1.33
times IRPs, whereas for imported products half were
0.77-1.26 times IRPs.
For nine medicines the government procured both
local and imported products, at variable prices and
quantities. For example, for ciprofloxacin five locally
produced products (total of 49.295 million tablets at
0.6580-0.7300 Birr per tablet) and one imported product
(13.6 million tablets at 0.5119 Birr per tablet) were pur-
chased. The lower priced imported product accounted
for only 21.6% of the total quantity of ciprofloxacin pur-
chased. For eight of the nine medicines, median pro-
curement prices of local products were higher (45%
more) than those of imported products. They ranged
from 1% more for doxycycline to 134% more for
erythromycin. The sole exception was locally produced
phenobarbitone which was a third of the price of the
imported product. For these eight medicines, the gov-
ernment would have saved about $3.7 million USD in
2013 if only the imported products were procured.
Availability and patient prices in the public sector
The mean availability of the medicines (whether
imported or locally produced) in the public sector out-
lets was 64% (Table 2). Local products had greater mean
availability (48%) than imported products (19%). The
availability for individual medicines was highly variable.
Branded generics (37%) were more commonly found
than INN generics (14%) for local products, whereas for
imported products the availability of branded generics
(10%) was similar to INN generics (9%). No originator
brands were found in the public sector.
Public sector patient prices for local products were
higher priced (median MPR = 1.44) than imported prod-
ucts (median MPR = 1.18) across the 10 medicines in the
paired analysis. Hence, patients were paying 22% more
when being dispensed local products.
Across all medicines (unpaired), patients in the public
sector were paying 23% more for locally produced
branded generics (median MPR = 1.41) than imports
(median MPR = 1.14). For INN generics, the difference
was minimal.
Public sector patient prices compared to government
procurement prices
For the 20 locally produced medicines that the govern-
ment procured and sold to patients in public sector
Table 2 Summary of government procurement prices, availability and patient prices in Ethiopia for locally produced and imported
medicines
Public sector Private sector
Locally produced Imported Locally produced Imported
Government procurement pricesa Number of medicines (products) 21 (48) 12 (13) N/A
Median MPR 1.20 0.84
Interquartile range 0.99 – 1.33 0.77 – 1.26
Availability Mean availability of all products
(local and imported) and product types
64% 73%
Mean availability of all product types
-Originator brands
-Branded generics
-INN generics
48%
0%
37%
14%
19%
0%
10%
9%
54%
0%
42%
13%
35%
9%
29%
3%
Patient prices Number of medicines (products) 10 (177) 10 (129) 15 (306) 15 (403)
Median MPR 1.44 1.18 1.85 5.42
Median interquartile range 1.08-1.56 1.02-1.42 1.71-1.96 2.65-9.34
Median MPR (products)a
-Originator brands
-Branded generics
-INN generics
-
1.41 (331)
1.45 (125)
-
1.14 (89)
1.41 (79)
-
1.71 (330)
2.17 (98)
20.35 (69)
4.33 (411)
2.08 (25)
aUnpaired analysis of prices
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outlets (paired analysis), patients were paying an average
of 1.17 times (17% more than) the government procure-
ment price (Table 3). For imported products (9 medi-
cines), patients were paying 1.53 times (53% more than)
the procurement price.
Availability and patient prices in the private sector
Mean availability of the medicines (imported or locally
produced) was 73% in the private sector (Table 3). Avail-
ability of local and imported products was 54% and 35%,
respectively, with variability for individual medicines.
Branded generics were more commonly found than INN
generics for local products (42% vs 13%) and imported
products (29% vs 3%). No locally produced originator
brands were found. The mean availability of imported
originator brands was 9%.
Overall, patient prices for local products (median
MPR = 1.85) were lower than imported products (median
MPR = 5.42) across the 15 medicines in the paired analysis
(Table 3). Overall, patients were paying 193% more for
imported products in the private sector.
Across all medicines (unpaired), imported branded ge-
nerics (median MPR = 4.33) were 153% higher priced than
local branded generics (median MPR = 1.71). Locally pro-
duced INN generics were slightly higher priced (median
MPR = 2.17) than imported INN generics (median MPR =
2.08). The few imported originator brands were far high
priced (median MPR = 20.35) compared to the generics.
Tanzania
Government procurement prices and quantities
For each medicine procured by the government, locally
produced or imported products were purchased but not
both. Of the 24 survey medicines, the government pro-
cured 9 locally produced medicines (9 products) and 7
imported medicines (10 products). Based on the INCO
terms, no price adjustments were needed. Overall, gov-
ernment procurement prices for local and imported
products were 0.69 and 1.34 times IRPs, respectively
(Table 4). For local products, half ranged from 0.65-0.97
times IRPs, whereas for imported products half were
0.69-4.85 times IRPs.
Availability and patient prices in the public sector
The mean availability of the medicines (imported or
locally produced) in the public sector outlets was 52%
(Table 4). Imported products had greater availability
(32%) than local products (21%), with variability for indi-
vidual medicines. Branded generics (15%) were more
commonly found than INN generics (6%) for local
products. The same was seen for imported medicines;
availability of branded and INN generics was 27% and
5%, respectively. Originator brands were rarely avail-
able at 4% and 0% for imported and local products,
respectively.
Public sector patient prices for local products were
higher than imported products across the 9 medicines
in the paired analysis (Table 4). Median MPRs of
local and imported products were 1.44 and 1.35 re-
spectively, hence patients were paying 7% more for
local products.
In an unpaired analysis of all medicines sold to pa-
tients in the public sector, locally produced branded ge-
nerics were 24% lower priced (median MPR = 1.67) than
imported branded generics (median MPR = 2.20). For
INN generics there was virtually no price difference be-
tween imports and products made in Tanzania in the
public sector.
Public sector patient prices compared to government
procurement prices
For the eight locally produced medicines that the gov-
ernment procured and sold to patients in public sector
outlets, patients were paying an average of 2.35 times
(135% more than) the procurement price (Table 3). For
imported products (7 medicines) patients were paying
1.65 times (65% more than) the procurement price.
Availability and patient prices in the private sector
The mean availability of imported or locally produced
medicines was 82% in the private sector. Availability of
local and imported products was 21% and 70%, respect-
ively, with variability for individual medicines. As with
the public sector, branded generics were more com-
monly found than INN generics for local products
(19% vs 2%) and imported products (58% vs 12%). No
locally produced originator brands were found. The
availability of imported originator brands was 7%.
Across 12 paired medicines, patient prices for local
and imported products were almost identical at 2.27 and
2.29 times IRP respectively although there was indi-
vidual variability e.g. imported sulfadoxine/pyrimethamine
Table 3 Median ratio between public sector patient prices and
procurement prices for locally produced and imported
medicines
Number of paired
medicines
Median ratio between
public sector patient
price MPR and public
sector procurement
price MPR
Ethiopia
Locally produced products 20 1.17
Imported products 9 1.53
Tanzania
Locally produced products 8 2.35
Imported products 7 1.65
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products (MPR = 10.91) were higher priced than the local
products (MPR = 7.27).
Across all medicines, imported branded generics
(median MPR = 2.97) were 48% higher priced than those
made locally (median MPR = 2.01), as shown in Table 4.
Imported INN generics (median MPR = 2.38) were 20%
lower priced than imported branded generics, but 15%
higher priced than locally produced INN generics
(median MPR = 2.07), however, only 12 locally produced
INN generics were found. Imported originator brands
(median MPR = 8.79) were far higher priced than
imported branded generics (median MPR = 2.97) and
INN generics (median MPR = 2.38).
Summary of results
The findings for Ethiopia and Tanzania show contrasting
situations. In Ethiopia, the government paid more over-
all for locally produced products compared to imports,
then applied a lower mark-up on these local products.
However, patient prices remained higher for local prod-
ucts compared to imports in public sector outlets. The
availability of local products was higher than for imports
in both the public and private sectors. In the private
sector, patients paid considerably more for imported
medicines.
In Tanzania, the government paid less for local prod-
ucts then applied a higher mark-up which resulted in pa-
tients paying slightly more for local products compared
to imported products in public sector outlets. The avail-
ability of local products was lower in public sector out-
lets compared to imports. In the private sector, imports
were far more available than local products and prices
were similar.
Discussion
A key objective of any national medicines policy is to
ensure the availability, affordability, and rational use of
essential medicines that are safe, effective and quality-
assured [12]. Local production is increasingly being con-
sidered as a means to improve medicine availability, and
improve medicine affordability through lower prices
compared to imports.
Substantial manufacturing of medicines takes place in
a number of LMICs. India and China are major pro-
ducers of generic medicines and their role has been crit-
ical in meeting public health needs not only in their own
countries but also in many other countries, including
those in Africa [8, 13]. But African countries are not
without local pharmaceutical industries. A 2005 survey
found that 37 of 46 African countries in the WHO
Africa region possessed some pharmaceutical manufac-
turing capacity [13]. Since then the number of local
manufacturers, their activities and product portfolios,
have continued to expand, but not in all African coun-
tries [13, 14]. Despite this growth, Africa manufactures
less than 2% of the medicines it consumes [15].
Compared to information on medicine prices and
availability in general, little is known about the impact of
local medicine production on prices and availability. In
2008, Mackintosh and Mujinja surveyed four rural dis-
tricts in Tanzania and found 46% of selected tracer med-
icines were made locally, and there were no significant
Table 4 Summary of government procurement prices, availability and patient prices in Tanzania for locally produced and imported
medicines
Public sector Private sector
Locally produced Imported Locally produced Imported
Government procurement pricesa Number of medicines (products) 9 (9) 7 (10) N/A
Median MPR 0.69 1.34
Interquartile range 0.65 – 0.97 0.69 –4.85
Availability Mean availability of all products
(local and imported) and product types
52% 82%
Mean availability of all product types
-Originator brands
-Branded generics
-INN generics
21%
0%
15%
6%
32%
4%
27%
5%
21%
0%
19%
2%
70%
7%
58%
12%
Patient prices Number of medicines (products) 9 (104) 9 (107) 12 (131) 12 (331)
Median MPR 1.44 1.35 2.27 2.29
Median interquartile range 1.00-1.83 1.29-1.75 2.07-2.95 2.18-3.14
Median MPR (products)a
-Originator brands
-Branded generics
-INN generics
-
1.67 (121)
1.98 (49)
3.48 (42)
2.20 (230)
1.97 (36)
-
2.01 (149)
2.07 (12)
8.79 (50)
2.97 (567)
2.38 (96)
aUnpaired analysis of prices
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patient price differences between medicines from the
three main countries of origin (India, Tanzania and
Kenya) [16]. In 2014, Mujinja et al. reported that medi-
cines produced in Tanzania were equally likely to be
found in rural and urban areas of the country, but
imported medicines displayed an ‘urban bias’ [17]. A fur-
ther study in Tanzania found a higher proportion of
medicines in public sector outlets were made locally
(22%) than in the private sector (9%) and the mission
sector (12%) [18]. Across all three sectors, 16%, 69% and
15% were made in Tanzania, India and Kenya, respect-
ively. In other countries, three studies found locally pro-
duced medicines had lower patient prices compared to
imports. Kuanpoth found locally produced ARVs had
lower patient prices compared to imported ARVs in
Vietnam [19]. Chowdury and Kabir found locally pro-
duced over-the-counter essential medicines in
Bangladesh had lower patient prices compared to im-
ports [20]. Sweileh et al. found lower patient prices for an-
tibiotics made locally compared to imports [21]. One
study, conducted by Shafie and Hassali in Malaysia, found
some locally produced generics had higher patient prices
compared to imports [22].
To support local producers, some governments have a
local preference policy when procuring medicines i.e.
they will pay more, up to a fixed percentage, for locally
produced medicines than for imports. The World Bank
supports this policy, while the Global Fund to Fight
AIDS, Tuberculosis and Malaria rejects it [23, 24]. In
Tanzania and Ethiopia the local preference policy is 15%
and 25%, respectively. In Tanzania, the government was
only buying one product per medicine so it was not pos-
sible to determine if this 15% local preference policy was
being applied. In Ethiopia, for nine of the 25 medicines
surveyed, one or more locally made products and one
import were purchased, at varying prices and quantities.
The reasons for this purchasing practice warrant further
study. Perhaps the manufacturers were unable to supply
greater quantities, or the government was buying from
multiple local manufacturers to provide broader local
support. The Ethiopian government’s 25% local prefer-
ence policy was being exceeded for some medicines.
Across the eight medicines where procurement prices
were lower for imports compared to locally produced
products, annual savings of $3.7 million (from a total
budget of $441 million) would result if only the lower-
priced imports were purchased.
Interestingly, the Ethiopian government applied a
smaller mark-up on higher-priced local products (17%),
than on lower-priced imported products (53%). This re-
duced the difference in patient prices between local and
imported products to 22% in public sector outlets. This
illustrates another way in which government supports
local producers.
The Tanzanian government was paying more for im-
ports compared to local products, but patients in public
sector outlets were paying more for local products com-
pared to imports. This was due to the different mark-
ups applied by the government (local products 135%,
imports 65%). Overall, imports were more available
(32%) than local products (21%) in the public sector.
The reasons for this should be investigated. What is
clear is that in both countries, the government does not
buy adequate quantities as medicine availability (local
and imports) in the public sector was only 52% in
Tanzania and 64% in Ethiopia.
The apparent consumer willingness to pay higher
prices for imported products, as seen in the private sec-
tor in Ethiopia, may reflect a perception that imports are
of higher quality. To boost local industries, the govern-
ment needs to ensure and publicise the equivalent qual-
ity of locally produced products.
Little is known about medicine price components in
the private sectors of both countries i.e. manufacturer’s
selling prices, mark-ups and other add-ons in the supply
chain that make up the final patient price. Local manu-
facturers may be selling at lower prices but add-ons may
significantly increase patient prices making products less
affordable for patients. Many WHO/HAI surveys have
found it challenging to measure price components [3],
so in this survey procurement and selling prices were
measured for only one wholesaler per country. This has
limited value so is not reported here. However, govern-
ments supporting local production should fully investi-
gate price components, including mark-ups, local taxes,
rebates and discounts, then regulate markets to ensure
their support results in more affordable medicines for
patients. South Africa has chosen to use a Single Exit
Price (SEP) mechanism that bans discounts and rebates
and provides transparent information about the prices of
medicines sold in the private sector [25].
Limitations of the methodology include (1) the rela-
tively low number of survey medicines (although over
2500 data points were generated per country) (2) meas-
uring availability only on the survey day (3) not identify-
ing clearance costs for imports purchased by the
Ethiopian government (4) not measuring all price com-
ponents in the pharmaceutical supply chain.
The findings from the survey in Ethiopia are consist-
ent with what is generally understood in some countries
in Africa i.e. that imported generics can be lower priced
than locally produced products. Initially prices of locally
produced medicines may be high, but WHO expects this
situation will not remain in the long term in countries
working to strengthen their local pharmaceutical indus-
try. In the short to medium term, governments need to
develop and implement policies through which they can
continue to support local production but, at the same
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time, prevent high prices being passed on to patients.
Different ways of achieving this dual policy objective
need to be explored.
In July 2015, two years after this study, Ethiopia
launched a ten year strategy and plan of action for
pharmaceutical manufacturing [26]. The objectives in-
clude improving access to medicines through the local
production of quality-assured pharmaceuticals, strength-
ening the FMHACA, promoting the production of APIs,
and creating a research and development platform. As
part of the strategy, the government is currently devel-
oping an incentive package that supports local manufac-
turers and ensures patient do not pay through higher
prices. This survey establishes a baseline for measuring
whether the plan of action results in improved access to
medicines through greater availability and lower prices.
Conclusions
The following are the key conclusions from this study:
 Systems to regularly and reliably monitor the
availability and prices of locally produced and
imported medicines need to be established to
assess the impact of local production on access to
medicines.
 Where a survey shows government procurement
prices of locally produced products are higher than
prices of imports, the procurement prices of all
medicines should then be reviewed. Local
preferences should also be reviewed to ensure
medicines are affordable to the population.
 Lower government procurement prices, whether for
local or imported products, should be passed on to
patients to improve medicine affordability.
 Governments supporting local production need to
ensure that where the prices of locally produced
medicines are found to be higher than imported
ones, they adopt appropriate policies so that high
prices are not passed on to patients, as this is
contrary to the objective of improving access
through local production.
 Supporting local manufacturers through fiscal and/or
non-fiscal incentives must be time-bound, developed
and implemented in a transparent way, and not paid
by patients through higher medicine prices. Balancing
local production policies is critically important. Such
policies should encourage foreign investments in
pharmaceutical manufacturing in developing
countries.
Following the two pilot studies that are reported
here, the survey tools were refined. The two national
reports of all the findings are available on HAI’s
website (http://haiweb.org/what-we-do/price-availability-
affordability/measuring-the-availability-and-prices-of-
locally-produced-and-imported-medicines) [27, 28].
The survey tools (manual and Excel workbook) will be
available on the website once finalised. Governments and
others who are interested in local production are encour-
aged to undertake a survey using these tools, then publish
reports of the findings on publicly-accessible websites, to
increase our understanding of the impact of local produc-
tion on prices and availability.
Abbreviations
FMHACA: Food, Medicine and Health Care Administration and Control
Authority of Ethiopia; HAI: Health Action International; ICTSD: International
Centre for Trade and Sustainable Development; INCO: International
Commercial; INN: International Non-proprietary Name; IRP: International
Reference Price; LMIC: Low- and Middle-income Country; MPR: Median Price
Ratio; NGO: Non-governmental Organisation; TFDA: Tanzanian Food and
Drug Administration; UNCTAD: United Nations Conference on Trade and
Development; WHO: World Health Organization
Acknowledgements
The authors are very grateful to the governments of Ethiopia and Tanzania,
and the WHO staff in the two countries, who supported the studies. We also
wish to thank the data collectors and data entry personnel. Importantly, we
wish to express our thanks to the staff in the outlets, and the government
officials, who so willingly provided the data.
Funding
Financial support was provided by the World Health Organization to adapt
and test the tools.
Availability of data and materials
The two national reports of all the findings are available on HAI’s website.
Authors’ contributions
ME and WK designed the methodology, trained the national investigators,
and reviewed, analysed and interpreted the data. ME drafted the manuscript.
WK reviewed the manuscript. TG and MJ-T collected the data, and reviewed
the manuscript. CV-V developed the data entry and analysis tool, and reviewed
the data and manuscript. ZM reviewed the methodology, interpretation of the
data and the manuscript. BR and MZ reviewed the manuscript. RL reviewed the
methodology, analyses, interpretation of the data and the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Given by authors
Ethics approval and consent to participate
Not applicable.
Author details
1Health Action International (HAI), Overtoom 60/II, 1054HK, Amsterdam,
Netherlands. 2Boston University School of Public Health, Boston, MA, USA.
3University of Western Cape, Cape Town, South Africa. 4University of Addis
Ababa, Addis Ababa, Ethiopia. 5Muhimbili University of Health and Allied
Sciences, Dar Es Salaam, Tanzania. 6Harvard Pilgrim Health Care Institute,
Boston, MA, USA. 7World Health Organization Regional Office for the Eastern
Mediterranean, Cairo, Egypt. 8Athena Institute, VU University, Amsterdam,
Netherlands.
Received: 3 June 2016 Accepted: 16 December 2016
References
1. World Health Organization. World Medicines Strategy 2004-2007. Geneva:
World Health Organization; 2004.
Ewen et al. Journal of Pharmaceutical Policy and Practice  (2017) 10:7 Page 8 of 9
2. World Health Organization/Health Action International. Measuring medicine
prices, availability, affordability and price components. 2nd edition. Geneva,
2008. Available at http://haiweb.org/what-we-do/price-availability-affordability/
collecting-evidence-on-medicine-prices-availability/. Accessed 8 Nov 2015.
3. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices,
availability, and affordability in 36 developing and middle-income countries:
a secondary analysis. Lancet 2009;373:240-249.
4. Van Mourik MSM, Cameron A, Ewen M, Laing RO. Availability, price and
affordability of cardiovascular medicines: a comparison across 36 countries
using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25.
5. Volman B. Direct costs and availability of diabetes medicines in low- and
middle-income countries. WHO/HAI 2008. Available at http://apps.who.int/
medicinedocs/en/d/Js18387en/. Accessed 8 Nov 2015.
6. Cameron A, Bansal A, Dua T, Hill S, Moshe S, Mantel-Teeuwisse A, Saxena S.
Mapping the availability, price and affordability of antiepileptic drugs in 46
countries. Epilepsia. 2012;53(6):962–69. doi:10.1111/j.1528-1167.2012.03446.x.
7. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and
affordability. An international comparison of chronic disease medicines.
WHO EMRO/HAI 2006.Available at http://apps.who.int/medicinedocs/
documents/s16180e/s16180e.pdf. Accessed 8 Nov 2015.
8. World Health Organization. Local production for access to medical
products. Developing a framework to improve public health. Geneva: World
Health Organization, Essential Medicines and Products: Policy brief; 2014.
9. Kaplan W. Local production and access to medicines in low- and middle-
income countries. A literature review and critical analysis. Geneva: World
Health Organization; 2013.
10. Kaplan WA, Ritz LS, Vitello M. Local production of medical technologies and
its effect on access in low and middle income countries: a systematic
review of the literature. South Med Rev. 2011;4(2):51–61.
11. World Health Organization. World Medicines Strategy 2008-2013. Geneva:
World Health Organization; 2008.
12. World Health Organization. How to develop and implement a national drug
policy. 2nd ed. Geneva: World Health Organization; 2001.
13. Berger M, Murugi J, Buch E et al. Strengthening pharmaceutical innovation
in Africa. Council on Health Research for Development (COHRED), New
Partnership for Africa’s Development (NEPAD) 2009. Available at http://
policycures.org/downloads/COHRED-NEPAD_Strengthening_
Pharmaceutical_Innovation_AfricaREPORT.pdf. Accessed 10 Sept 2016.
14. Mackintosh M, Banda G, Tibandebage P, Wamae W (Eds.).Making medicines
in Africa. The political economy of industrializing for local health.
International Political Economy Series, 2015. Available at http://www.
palgrave.com/us/book/9781137546463. Accessed 10 Sept 2016.
15. Lopes C. Making medicine in Africa - the untapped possibilities that could
save millions of lives. 17 February 2015. Available at http://mgafrica.com/
article/2015-02-17-manufacturing-pharmaceuticals-in-africa-the-untapped-
opportunity-that-could-save-countless-lives. Accessed 8 Oct 2016.
16. Mackintosh M, Mujinja PG. Pricing and competition in essential medicines
markets: the supply chain to Tanzania and the role of NGOs. IKD Working
Paper No. 32. Open University Research Centre on Innovation Knowledge
and Development. Available at http://www.open.ac.uk/ikd/sites/www.
open.ac.uk.ikd/files/files/working-papers/ikd-working-paper-32.pdf.
Accessed 8 Oct 2016.
17. Mujinja P, Mackintosh M, Justin-Temu M, Wuyts M. Local production of
pharmaceuticals in Africa and access to essential medicines: ‘urban bias’ in
access to imported medicines in Tanzania and its policy implications.
Globalization and Health. 2014;10:12.
18. Israel C, Mackintosh M, Tibandebage P, Mhede E, Mujinja PGM. Improving
the supply chain for the health sector: what role for local manufacturing?
Policy research for development. Working paper 14/6. Available at http://
www.repoa.or.tz/documents/REPOA_WP_14_6.pdf. Accessed 8 Oct 2016.
19. Kuanpoth J. Patents and access to antiretroviral medicines in Vietnam after
World Trade Organization accession. J World Intell Prop. 2007;10:201–24.
20. Chowdury N, Kabir ER. Per pill price differences across therapeutic
categories: a study of the essential drug brands marketed by multinational
and local pharmaceutical companies in Bangladesh. African J Marketing
Mgt. 2009;1:220–6.
21. Sweileh W, Jaradat N, Mustafa A. Antibiotic drug cost variations in Palestine:
physicians and patients dilemma. An-Najah Univ J Res. 2004;18(1):73–9.
22. Shafie AA, Hassali MA. Price comparison between innovator and generic
medicines sold by community pharmacies in the state of Penang, Malaysia.
J Generic Med. 2008;6:35–42.
23. The World Bank. Procurement of goods, works, and non-consulting services
under IBRD loans and IDA credits and grants by World Bank Borrowers.
Washington: World Bank; 2011.
24. Global Fund to Fight AIDS, Tuberculosis and Malaria. Guide to Global Fund
policies on procurement and supply management of health products.
Geneva: Global Fund; 2012.
25. Gray AL. Medicine pricing interventions-the South African experience.
Southern Med Review. 2009;2(2):15–9.
26. Ministry of Health and Ministry of Industry, Federal Democratic Republic of
Ethiopia. National strategy and plan of action for pharmaceutical
manufacturing development in Ethiopia (2015-2025). Developing the
pharmaceutical industry and improving access. July 2015. Available at
http://www.who.int/phi/publications/Ethiopia_strategy_local_poduction.pdf.
Accessed 12 Nov 2015.
27. World Health Organization/Health Action International. Prices and
availability of locally produced and imported medicines in Ethiopia.
Available at http://haiweb.org/what-we-do/price-availability-
affordabilitymeasuring-the-availability-and-prices-of-locally-produced-and-
imported-medicines/ . Accessed 5 Dec 2016.
28. World Health Organization/Health Action International. Prices and
availability of locally produced and imported medicines in Tanzania.
Available at http://haiweb.org/what-we-do/price-availability-affordability/
measuring-the-availability-and-prices-of-locally-produced-and-imported-
medicines. Accessed 5 Dec 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ewen et al. Journal of Pharmaceutical Policy and Practice  (2017) 10:7 Page 9 of 9
